Business Wire

Lightbits Grows Revenues By Over 5X in 2020 While Driving Innovation Through Technology Advancements and Patents

Share

Lightbits Labs, the pioneer and leader in NVMe™ over TCP (NVMe/TCP) software-defined storage, increased sales by more than 500 percent through a significant uptick in infrastructure as a service (IaaS), software as a service (SaaS), financial services, and video gaming customers.

Sales growth was fueled in part by the company’s strong partnerships, to which Intel was added in late September and also included new funding from Intel Capital. The partnership is designed to propel development of disaggregated storage solutions to solve the challenges of today’s data center operators who are craving improved storage efficiency and capacity utilization while maintaining compatibility with existing infrastructure without compromising performance and simplicity. This strategic partnership includes technical co-engineering, go-to-market collaboration, as well as the financial investment.

“In so many ways and for so many people 2020 was a very difficult year. Lightbits is fortunate that we were able to keep our employees safe through remote work, while also achieving and exceeding our goals for the year – including growing our customer base, enhancing our products, and expanding our partnerships and investors,” said Eran Kerzner, CEO. “We fully anticipate a strong surge in our sales throughout 2021.”

Last year, Lightbits announced significant product advancements, introducing LightOS™ 2.0 in June enabling full cloud-native persistent storage with high availability. The technological innovation solidified the company's position as a leader in scalable and efficient cloud-native storage that’s easy to consume for customers' private, hybrid, and edge cloud deployments. In December, the company released LightOS™ 2.1 that further enhances high-performance, scalability, and low latency so Lightbits’ customers can unleash hyperscale storage, but at a fraction of the cost of even the most advanced cloud storage offerings. As an example, Lightbits’ LightOS outperforms even the latest Amazon EBS io2 Block Express volumes with 5 times lower latency (200µs), 6 times the IOPS per volume (1.5M), twice the throughput per volume (8GB/s), 4 times larger volume size (256TB), and has features such as resizable volumes and multi-attach that are still roadmap items for io2 Block Express.

Through these advancements, Lightbits expanded the use cases for its patented solutions, including NVMe as a Service, as part of the IaaS umbrella. For financial services, use cases expanded to include database acceleration and Monte Carlo simulation. And under the SaaS umbrella, Lightbits LightOS gained traction as a high-performance replacement for Ceph.

In addition, Lightbits applied for five new patents that were accepted by the U.S. Patent Office, bringing the number of patents held by Lightbits to 20. The newly minted patents improve key functions within the NVMe/TCP storage architecture and help Lightbits protect its innovative approach to improving storage capacity utilization, reducing latency, and improving garbage collection features.

“With its blend of performance and high availability based around industry standards, NVMe/TCP offers a compelling value proposition for those needing extremely high performance in the composable block storage market,” said Eric Burgener, Research Vice President, Infrastructure Systems, Platforms and Technologies Group at IDC Research. “Lightbits Labs has significantly contributed to the NVMe/TCP standard and is continuing to improve upon the standard with its latest IP.”

Details on the new and existing Lightbits Labs patents can be found in the links below:

Among the milestones, 2020 drove several notable industry recognitions including:

Additional Resources:

About Lightbits Labs™

Lightbits Labs’ mission is to lead the cloud-native data center transformation by delivering scalable and efficient software defined storage that is easy to consume. Founded in 2016, Lightbits brings the agility of hyperscale storage to private clouds and edge clouds. The company pioneered NVMe/TCP so the solution is easy to deploy at scale, while delivering performance that is similar to local flash. Lightbits Labs is backed by strategic investors including Cisco Investments, Dell Technologies Capital, Intel Capital, and Micron, as well as top investors and VCs including Avigdor Willenz, Lip-Bu Tan, Marius Nacht, SquarePeg Capital, and WRVI Capital.

Visit www.lightbitslabs.com or contact us at info@lightbitslabs.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Alan Ryan
pr@lightbitslabs.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye